Walder Wyss advises Novo Holdings on Catalent acquisition

Walder Wyss advised Danish life science investor Novo Holdings through its acquisition of American pharma multinational Catalent.

Globally active in the fields of life sciences and healthcare, Novo Holdings acts as the only asset manager and parent company for the Novo Nordisk Foundation. The latter will in fact incorporate, as a result of the transaction,  three units out of Catalent’s global fleet of 50 production sites.

Catalent is pharmaceutical multinational, specialising in gene therapies and clinical supply solutions. It serves pharmaceutical, biotech, and consumer health companies all across the globe.

The team

The Walder Wyss team handling the Swiss aspects of the transaction was co-led by partner Luc Defferrard (pictured right) and counsel Iliana Djagova (pictured left), both corporate/M&A, supported by partner Simone Wetzstein (employment law), partner Fabienne Limacher (tax), counsel Sylvia Anthamatten (IP/IT), counsel Julia Lehner (real estate), counsel Fabian Looser (employment), senior associate Erik Lanz (corporate/M&A), senior associate Simon Olstein (life sciences) and associate Christoph Burckhardt  (corporate/M&A).

flavio.caci@lcpublishinggroup.com

SHARE